Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
19.89
-0.79 (-3.82%)
Nov 17, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 287.45 | 804.9 | 434.25 | 1,967 | 1,545 | 1,478 |
Trading Asset Securities | 2,504 | 2,049 | 2,222 | 1,514 | 1,719 | 1,976 |
Cash & Short-Term Investments | 2,791 | 2,854 | 2,656 | 3,481 | 3,264 | 3,454 |
Cash Growth | 2.57% | 7.45% | -23.69% | 6.65% | -5.49% | 239.50% |
Accounts Receivable | 495.07 | 460.05 | 483.61 | 351.93 | 839.62 | 322.32 |
Other Receivables | 10.03 | 11.56 | 20.81 | 4.07 | 7.72 | 4.67 |
Receivables | 505.11 | 471.61 | 504.42 | 356.01 | 847.35 | 326.99 |
Inventory | 323.55 | 343.67 | 362.18 | 346.25 | 364.2 | 242.19 |
Prepaid Expenses | - | 2.13 | 0.05 | - | - | - |
Other Current Assets | 37.86 | 36.14 | 48.58 | 47.12 | 89.71 | 28.1 |
Total Current Assets | 3,658 | 3,708 | 3,571 | 4,230 | 4,565 | 4,051 |
Property, Plant & Equipment | 564.14 | 617.48 | 726.07 | 767.3 | 679.48 | 308.98 |
Long-Term Investments | 89.07 | 79.96 | 54.83 | 47.3 | 22.31 | 18.48 |
Goodwill | 130.49 | 130.49 | 130.49 | 130.49 | 130.49 | - |
Other Intangible Assets | 75.79 | 86.63 | 95.19 | 101.24 | 49.7 | 16.65 |
Long-Term Accounts Receivable | 0.36 | 0.06 | 0.15 | - | - | - |
Long-Term Deferred Tax Assets | 186.01 | 166.62 | 146.04 | 106.51 | 67.12 | 24.87 |
Long-Term Deferred Charges | 182.55 | 220.12 | 278.91 | 280.54 | 318.31 | 145 |
Other Long-Term Assets | 16.11 | 19 | 45.51 | 82.53 | 172.69 | 42.25 |
Total Assets | 4,902 | 5,028 | 5,049 | 5,746 | 6,005 | 4,607 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 105.53 | 91.59 | 90.4 | 146.82 | 318.78 | 118.76 |
Accrued Expenses | 115.42 | 142.43 | 129.74 | 112.52 | 258.07 | 104.7 |
Short-Term Debt | 716.83 | 686.68 | 551.32 | 1,134 | 272.21 | - |
Current Portion of Leases | 42.58 | 28.43 | 57.03 | 46.16 | 58.25 | 31.25 |
Current Income Taxes Payable | 33.87 | 2.23 | 0.6 | 0.03 | 0.54 | 20.02 |
Current Unearned Revenue | 63.15 | 72.14 | 54.87 | 55.92 | 214.55 | 95.03 |
Other Current Liabilities | 11.25 | 18.36 | 19.36 | 24.09 | 31.67 | 17.5 |
Total Current Liabilities | 1,089 | 1,042 | 903.33 | 1,520 | 1,154 | 387.26 |
Long-Term Leases | 97.5 | 127.33 | 143.36 | 106.89 | 127.68 | 59.93 |
Long-Term Unearned Revenue | 70.2 | 61.76 | 48.38 | 21.38 | 19.25 | 16.24 |
Long-Term Deferred Tax Liabilities | 1.46 | 1.03 | 1.26 | 1.51 | 11.19 | 0.87 |
Other Long-Term Liabilities | 4.79 | 4.75 | 8.72 | 67.6 | 80.92 | 15.52 |
Total Liabilities | 1,263 | 1,237 | 1,105 | 1,717 | 1,393 | 479.83 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 516.99 | 397.73 | 402.13 | 400.01 | 400.01 | 400.01 |
Additional Paid-In Capital | 2,224 | 2,339 | 2,512 | 2,442 | 2,429 | 2,422 |
Retained Earnings | 888.26 | 1,063 | 1,139 | 1,209 | 1,780 | 1,305 |
Treasury Stock | -5.01 | -3 | -104.4 | -20.01 | - | - |
Comprehensive Income & Other | -0.68 | -0.63 | -3.97 | -1.72 | - | - |
Total Common Equity | 3,623 | 3,796 | 3,945 | 4,029 | 4,609 | 4,127 |
Minority Interest | 16.54 | -4.82 | -1.63 | -0.11 | 3.2 | - |
Shareholders' Equity | 3,640 | 3,791 | 3,944 | 4,029 | 4,612 | 4,127 |
Total Liabilities & Equity | 4,902 | 5,028 | 5,049 | 5,746 | 6,005 | 4,607 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 856.9 | 842.44 | 751.71 | 1,287 | 458.14 | 91.18 |
Net Cash (Debt) | 1,934 | 2,012 | 1,905 | 2,194 | 2,806 | 3,362 |
Net Cash Growth | 4.00% | 5.62% | -13.19% | -21.81% | -16.56% | 230.91% |
Net Cash Per Share | 2.95 | 3.73 | 4.05 | 4.28 | 5.41 | 7.13 |
Filing Date Shares Outstanding | 516.99 | 517.05 | 517.16 | 516.1 | 520.01 | 520.01 |
Total Common Shares Outstanding | 516.99 | 517.05 | 517.16 | 516.1 | 520.01 | 520.01 |
Working Capital | 2,569 | 2,666 | 2,668 | 2,711 | 3,411 | 3,664 |
Book Value Per Share | 7.01 | 7.34 | 7.63 | 7.81 | 8.86 | 7.94 |
Tangible Book Value | 3,417 | 3,579 | 3,720 | 3,798 | 4,429 | 4,111 |
Tangible Book Value Per Share | 6.61 | 6.92 | 7.19 | 7.36 | 8.52 | 7.90 |
Machinery | - | 720.6 | 712.88 | 656.11 | 513.97 | 250.31 |
Construction In Progress | - | 63.86 | 69.42 | 127.48 | 69.44 | - |